Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?

Giuseppe Buono, Lorenzo Gerratana, Michela Bulfoni, Nicoletta Provinciali, Debora Basile, Mario Giuliano, Carla Corvaja, Grazia Arpino, Lucia Del Mastro, Sabino De Placido, Michele De Laurentiis, Massimo Cristofanilli, Fabio Puglisi

Research output: Contribution to journalReview article

Abstract

Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.

Original languageEnglish
Pages (from-to)73-83
Number of pages11
JournalCancer Treatment Reviews
Volume73
DOIs
Publication statusE-pub ahead of print - Jan 11 2019

Fingerprint

Breast Neoplasms
DNA
Neoplasms
Biopsy
Precision Medicine
Resource Allocation
Quality of Life
Technology
Delivery of Health Care
Survival
Therapeutics

Cite this

Circulating tumor DNA analysis in breast cancer : Is it ready for prime-time? / Buono, Giuseppe; Gerratana, Lorenzo; Bulfoni, Michela; Provinciali, Nicoletta; Basile, Debora; Giuliano, Mario; Corvaja, Carla; Arpino, Grazia; Del Mastro, Lucia; De Placido, Sabino; De Laurentiis, Michele; Cristofanilli, Massimo; Puglisi, Fabio.

In: Cancer Treatment Reviews, Vol. 73, 11.01.2019, p. 73-83.

Research output: Contribution to journalReview article

Buono, G, Gerratana, L, Bulfoni, M, Provinciali, N, Basile, D, Giuliano, M, Corvaja, C, Arpino, G, Del Mastro, L, De Placido, S, De Laurentiis, M, Cristofanilli, M & Puglisi, F 2019, 'Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?', Cancer Treatment Reviews, vol. 73, pp. 73-83. https://doi.org/10.1016/j.ctrv.2019.01.004
Buono, Giuseppe ; Gerratana, Lorenzo ; Bulfoni, Michela ; Provinciali, Nicoletta ; Basile, Debora ; Giuliano, Mario ; Corvaja, Carla ; Arpino, Grazia ; Del Mastro, Lucia ; De Placido, Sabino ; De Laurentiis, Michele ; Cristofanilli, Massimo ; Puglisi, Fabio. / Circulating tumor DNA analysis in breast cancer : Is it ready for prime-time?. In: Cancer Treatment Reviews. 2019 ; Vol. 73. pp. 73-83.
@article{793878900ab741b3a89157aa44b1cb76,
title = "Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?",
abstract = "Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.",
author = "Giuseppe Buono and Lorenzo Gerratana and Michela Bulfoni and Nicoletta Provinciali and Debora Basile and Mario Giuliano and Carla Corvaja and Grazia Arpino and {Del Mastro}, Lucia and {De Placido}, Sabino and {De Laurentiis}, Michele and Massimo Cristofanilli and Fabio Puglisi",
note = "Copyright {\circledC} 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2019",
month = "1",
day = "11",
doi = "10.1016/j.ctrv.2019.01.004",
language = "English",
volume = "73",
pages = "73--83",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Circulating tumor DNA analysis in breast cancer

T2 - Is it ready for prime-time?

AU - Buono, Giuseppe

AU - Gerratana, Lorenzo

AU - Bulfoni, Michela

AU - Provinciali, Nicoletta

AU - Basile, Debora

AU - Giuliano, Mario

AU - Corvaja, Carla

AU - Arpino, Grazia

AU - Del Mastro, Lucia

AU - De Placido, Sabino

AU - De Laurentiis, Michele

AU - Cristofanilli, Massimo

AU - Puglisi, Fabio

N1 - Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2019/1/11

Y1 - 2019/1/11

N2 - Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.

AB - Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity. Several techniques are currently available for ctDNA extraction and analysis, each with its preferential case scenarios and preanalytical implications which must be taken into consideration to effectively support clinical decision-making and to better highlight its clinical utility. Aim of this review is to summarize both analytical developments and clinical evidences to offer a comprehensive update on the deployment of ctDNA in breast cancer's (BC) characterization and treatment.

U2 - 10.1016/j.ctrv.2019.01.004

DO - 10.1016/j.ctrv.2019.01.004

M3 - Review article

C2 - 30682661

VL - 73

SP - 73

EP - 83

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -